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Objective: To test whether an ultramolecular dilution of homeopathic Thyroidinum has 
an effect over placebo on weight reduction of fasting patients in so-called 'fasting 
crisis'. 
Design: Randomised, placebo-controlled, double-blind, parallel group, monocentre 
study. 
Setting/location: Hospital for internal and complementary medicine in Munich, 
Germany. 
Subjects: Two hundred and eight fasting patients encountering a Stagnation or increase 
of weight after a weight reduction of at least 100 g/day in the preceding 3 days. 
Intervention: One oral dose of Thyroidinum 30cH (preparation of thyroid gland) or 
placebo. 
Outcome Measures: Main outcome measure was reduction of body weight 2 days after 
treatment. Secondary outcome measures were weight reduction on days 1 and 3, 15 
complaints on days 1-3, and 34 laboratory findings on days 1-2 after treatment. 
Results: Weight reduction on the second day after medication in the Thyroidinum 
group was less than in the placebo group (mean difference 92 g, 95% confidence 
interval 7-176 g, P::0.034). Adjustment for baseline differences in body weight and rate 
of weight reduction before medication, however, weakened the result to a non-
significant Ievei (P:0.094). There were no differences between groups in the secondary 
outcome measures. 
Conclusions: Patients receiving Thyroidinum had less weight reduction on day 2 after 
treatment than those receiving placebo. Yet, since no significant differences were 
found in other outcomes and since adjustment for baseline differences randered the 
difference for the main outcome measure non-significant, this result must be 
interpreted with caution. Post hoc evaluation of the data, however, suggests that by 
predefining the primary outcome measure in a different way, an augmented reduction 
of weight on day 1 after treatment with Thyroidinum may be demonstrated. Both 
results would be compatible with homeopathic doctrine (primary and secondary effect) 
as weil as with findings from animal research. Homeopathy (2002) 91, 197-206. 
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One of the most controversial features of homeopathy 
is the principle of 'potentisation'. Indeed, the claim 
that ultramolecular dilutions of homeopathic remedies 
might be therapeutically effective is contrary to a basic 
paradigm of pharmacology that holds that without 
active substance no pharmacological efficacy is to be 
expected. Y et, a number of clinical tri als seem to show 
some evidence for ultramolecular effects, 1,2 but the 
methodological quality of many studies is inadequate. 
Recent commentators2•3 have favoured broad out-
come studies of homeopathy in 'real world' settings 
over trials against placebo, but this approach can only 
demonstrate effectiveness of homeopathic practice in 
general, not its superiority over sham treatment within 
the same therapeutic setting. For investigation of the 
efficacy of homeopathic ultramolecular dilutions, there 
is still no method other than randomised controlled 
clinical trials based on clinical models that minimise 
the number of variables. 
In order to bypass many difficulties of 'real world' 
homeopathic practice such as selection of symptoms, 
remedy, and potency, aggravations, changing the 
medicine, relying on subjective data (pain, complaints), 
etc, we designed and conducted a controlled clinical 
trial of a clinical homeopathic treatment which 
followed good clinical practice (GCP) guidelines, 
measuring its effect on objective as well as subjective 
outcome parameters under standardised conditions. As 
clinical model we chose the influence of a 10-60 (30c) 
dilution of Thyroidinum (preparation of thyroid gland) 
on the rate of weight reduction of fasting patients 
encountering an unexpected Stagnation or increase of 
body weight. 
Fasting is known to reduce triiodothyronine (T3) 
plasma levels, mainly due to an inhibition of extra-
thyroidal conversion of thyroxine (T4) to triiodothyr-
onine (T3), accompanied by a corresponding increase 
of biologically inactive reverse T3.4-6 This low-T3-
state, ie reduction of the metabolically active thyroid 
hormone, is regarded as an adaptive mechanism to 
save energy expenditure by reducing protein and fat 
catabolism and thermogenesis.7- 9 T3-treatment, on the 
other hand, augments reduction of body weight m 
fasting patients. 10- 12 
During fasting, patients usually lose weight in 
declining amounts ranging from about 1.0 kgjday 
initially to about 0.3 kgjday after 1 or 2 weeks. Despite 
food restriction, on some days of the fasting period a 
stagnation or even increase of weight, accompanied 
with typical psychic and somatic complaints (so-called 
'fasting crisis') may occur. According to the clinical 
experience of doctors at our hospital, treatment with 
high dilutions of Thyroidinum was often followed by an 
increase in the rate of weight reduction. Considering 
the pathophysiological relations between fasting, 
thyroid hormone, and weight reduction, we decided 
to test whether treatment of a 'fasting crisis' with 
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Thyroidinum 30cH yields different objective and sub-
jective outcomes than treatment with placebo. 
Subjects and methods 
This trial was a randomised, placebo-controlled, 
double-blind, parallel group, monocentre study con-
ducted at the Krankenhaus für Naturheilweisen. At 
this Munich-based hospital with a homeopathic tradi-
tion going back to its foundation in 1883, fasting 
therapy is applied to a broad spectrum of diagnoses 
including hypertension, diabetes, osteoarthritis, bron-
chial asthma, migraine, etc. Treatment consists of a 
160 kcal diet with unlimited mineral water and herbal 
teas. 
During the trial, body weight of all fasting patients 
was checked daily under standardised conditions and 
supervision of attending nurses. The three human 
weighing machines used (type SECA 930) were 
identical, purchased recently, accurate to ± 100 g, 
compatible with EC-guide1ine 90/384/EWG, checked 
daily by the hospital staff and double checked every 
two months by the principal investigator. Patients 
being weighed wore nothing but a night-shirt provided 
by the hospital (the same every day), with an empty 
bladder. In addition, all patients completed question-
naires on quality of life before and after fasting and 
reported their caloric and liquid intake, activities and 
complaints daily. Doctors documented history, exam-
ination, diagnoses, medication, therapies, and labora-
tory findings at the beginning and the end of fasting. 
Of these fasting patients those who - having lost at 
least 100 gjday on three consecutive days (run-in 
period) - encountered a spontaneous stagnation or 
increase of body weight were reported on the same day 
by a nurse to the principal investigator or ( on 
weekends) to the ward doctor to be checked for 
eligibility (see Figure 1). Patients in the study had 
blood tests on three successive days (days 0, 1, and 2), 
always at the same time, to screen for differences in the 
laboratory data. Immediately after the first blood 
sample was taken, study medication was administered: 
one dose of five pellets of Thyroidinum 30cH or 
placebo. Patients continued to be weighed daily and 
report their complaints, physical activities, caloric and 
liquid intake etc in structured diary-forms on each of 
the following 3 days (days 1-3). 
Originally, the main outcome measure was prespe-
cified to be reduction of body weight on day 1 after 
medication (later this was changed to day 2, see 
discussion). Secondary outcome measures were deter-
mined tobe the reduction of body weight on days 2-3 
(later: days 1 and 3), the course of 34 1aboratory data 
from days 0 to 1 and 2, respectively (blood count, 
urea, creatinine, uric acid, cholesterol, high-density 
Iipoprotein, low-density Iipoprotein, triglycerides, iron, 
bilirubin, total protein, electrophoresis, gamma gluta-
mate transpeptidase, glutamate pyruvate transami-
lnclusion criteria 
Stagnation or increase of body weight 
Fasting 3 days so far and 3 more days prospectively 
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Body weight reduction during the last 3 days of at least 100 g on each single day 
Compliance with the documentation requirements 
Complete data in patients' diaries and checklists so far 
Majority (age > 18 years) 
Signed informed consent 
Exclusion criteria 
Severe endocrinologic, metabolic, hematologic, infectious, cardiovascular, respiratory, hepatic, renal, 
tumorous or psychiatric disease 
lntake of thyroid hormones, antithyroid drugs, strong psychochemicals, opiates or iodine containing 
medication 
Radioiodine therapy or thyroidectomy in the past 
Participation in another clinical trial 
Having already participated in this study 
Abuse of alcohol or drugs 
Pregnancy or breast-feeding 
lncorrectness in the fasting diet 
Figure 1 lnclusion and exclusion criteria. 
nase, glutamate oxalacetate transaminase, alkaline 
phosphatase, sodium, potassium, calcium, magnesium, 
glucose, triiodothyronine, thyroxine, thyroid stimulat-
ing hormone, fibrinogen), and 15 complaints on days 
1-3 (headache, dizziness, impaired vision, hunger, 
nausea, palpitation, difficulty in breathing, backache, 
muscle pain, circulatory disturbance, faintness, irrit-
ability, disturbed sleep, depression, sensitivity to cold), 
reported daily on a five-item scale. Additionally, 
physicians and patients were asked for a global 
assessment of well-being, tolerability, and effectiveness 
of the medication on day 3 after administration. 
The target sample size was estimated on the basis of 
data from fasting patients of the previous year. 
Postulating a mean difference in weight reduction of 
100 g between the groups and assuming a standard 
deviation of 300 g and a drop-out rate of 10%, to 
achieve an alpha of 0.05 and a power of 0.8, a sample 
size of 300 patients was calculated. Expecting a 
recruitment of two patients per week, the study was 
scheduled for 3 years. According to the sequential plan 
after 50 patients an interim analysis (for P<0.005) and 
after 300 patients the final analysis (for P<0.048) were 
determined. 13•14 A significant result of the interim 
analysis would have led to termination of the study. 
Statistical analyses were intended to be confirmatory 
for the primary and exploratory for the secondary 
outcome measures. Depending on the Normality 
distribution of the weight reduction either the two-
tailed t test or the Mann-Whitney V-test was to be 
applied (intention-to-treat). The analysis was carried 
out with SPSS 10.0 software and a Pentium II 
processor. 
Assignment and blinding 
The study medication was manufactured by a German 
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(DHU, Karlsruhe). Powder of dried thyroid gland of 
German pigs was triturated, diluted, and succussed in 
the ratio 1: 100, 30 times, according to the German 
homeopathic pharmacopoeia (HAB). Pellets of sucrose 
impregnated with the final dilution constituted the 
active medication. Another part of the same Iot of 
sucrose pellets was designated as the control medica-
tion. Specimens of both sets were kept for possible 
later investigation. 
A randomisation Iist was generated by means of a 
validated computer program in an external biometric 
institution (BZT, Munich), in blocks of six, stratified for 
males and females. Under supervision of the biome-
trician, an external pharmacist filled opaque, sequen-
tially numbered containers with five pellets each-either 
out of the Thyroidinum or the placebo set of the study 
medication. Finally, the Iist with the codewas deposited 
in a sealed opaque envelope in the safe of the biometric 
centre. The biometrician and the pharmacist, ie the only 
persons who had seen the code, signed an agreement to 
maintain absolute secrecy. The labelled containers were 
stored in the pharmacy of the hospital. 
Every container removed and administered to a 
patient was registered stating randomisation number, 
date, time and name of the patient. Since nobody in the 
hospital knew the code or perceived any difference in 
appearance or taste between the study medications, 
blinded assignment was guaranteed. Prior to inclusion 
every patient signed informed consent. The protocol 
was approved by the ethical committee of the Bavarian 
board of physicians. 
Interim analysis 
After 1 year 'semi-deblinding' and interim analysis were 
carried out. 'Semi-deblinding' means that information 
on which individuals belong to groups A or B was 
revealed, but not which was the treatment and which the 
placebo group. Per-protocol analysis (n =53) showed a 
mean reduction of body weight on the day after 
medication of 476 g (SD 351 g, n 29) in group A and 
57 5 g (SD 251 g, n = 24) in group B. Since the P value 
(0.25) was not <0.005, the study was continued. A 
comparison of reduction of weight on days 1, 2, and 3, 
however, showed that the most striking difference 
between groups appeared on the second rather than 
on the first day after medication (181 g on day 2, vs 99 g 
on day 1). Hence, in an amendment to the protocol the 
main outcome measure was changed from weight 
reduction on the first to weight reduction on the second 
day. This amendment was written down, signed and 
sent to the biometric centre (where it was kept in a safe). 
After 3 years recruitment 181 patients had been 
recruited compared to the estimated number of 300. To 
ensure that it was reasonable to stop and analyse the 
study at this point, a stochastic curtailment was carried 
out by an external statistician on the basis of the mean 
values and standard deviations of the weight reduction 
on day 2 of the semi-deblinded groups A and B. It was 
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determined that, provided the distribution of the main 
outcome measure did not change, 190 patients should 
suffice to close the study and yet reach its aim with a 
probability of 0.96. 15 
Results 
Participant ftow and follow-up 
At the Krankenhaus für Naturheilweisen, 499 fasting 
patients were reported to be encountering a stagnation 
or increase of body weight and were checked for 
inclusion and exclusion criteria. Two hundred and 
eleven patients were eligible and allocated a randomi-
sation number. Three patients (two thyroidinum, one 
placebo) withdrew consent before opening the contain-
er. Thus, 208 patients actually received study medica-
tion. Although in 14 cases it was noticed that by 
mistake on the part of the physician on duty one of the 
eligibility criteria had been overlooked, all 208 patients 
were followed up and analysed (Figure 2). 
Analysis 
After 3 years and 3 months final file-closing, full 
deblinding, and analysis took place. Study medication 
had been administered to 208 patients. Fourteen 
patients showed one minor deviation from the protocol 
each, such as not having had a reduction of weight for 
3 consecutive days preceding the stagnation of weight 
(five verum, one placebo), not having had a stagnation 
or increase of weight on day 0 (one verum), having 
taken thyroid hormone ( one verum, one placebo) or an 
iodine containing drug ( one verum, one placebo) 
during the study period, having had radioiodine 
therapy (one verum), not being adult (one verum) or 
having already been subjected in the study ( one verum 
patient, 8 months previously). There were no drop-
outs. Thus, 194 patients fulfilled all requirements per-
protocol. One severe adverse effect (transient ischemic 
attack with hemiplegia) occurred, the code remained 
unbroken. On analysis it turned out that this patient 
h~d received placebo (Table 1). 
Statistical analysis (intention-to-treat) showed that 
the average reduction of body weight 2 days after 
medication was significantly lower in the Thyroidinum 
group (347g, SD 304g, 95% CI 287-407g, n=l02) 
than in the placebo group (439 g, SD 313 g, 95% CI 
378-499 g, n 106). The difference between the sample 
means was -92 g (95% CI -176 to -7 g), correspond-
ing to a P value of P=0.034 (t=2.14, df=206). Per-
protocol analysis yielded similar results: difference 
between the means was -93 g (95% CI 179 to 
-7g) and P 0.033 (t=2.14, df=192). Although the 
daily reduction of body weight followed approximately 
a normal distribution, to doublecheck, the non-
parametric Mann-Whitney U-test was also performed 
(intention-to-treat) with similar result (Z = -2.15, 
P = 0.032). Removing outliers increased rather than 
decreased significance (see Table 2). 
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Participant flow and follow up 
Fasting patients of the hospital encountering 
a stagnation/increase of body weight 
Reported to the study physician (n=499) 
lneligible because of inclusion and/or exclusion 
criteria (n=288): not Iasting 3 days so far (n=30), 
not fasting 3 more days prospectively (n=100), 
no body weight reduction du ring the last 3 days of 
at least 100 g/d (n=46), no stagnation or increase of 
weight (n=25), incomplete data in patients' diaries and 
checklists (n=23), no written consent (n=21 ), severe 
disease (n=14), intake of thyroid hormone (n=68) or 
iodine containing medication (n= 22), strumectomy 
(n=5), having already participated in this study (n= 32), 
incorrectness in Iasting diet (n=11) [multiple reasons 
possible] 




Received thyroidinum (n=102) 
Did not receive thyroidinum, withdrawal of 
consent (n=2) 
Deviations from the protocol (n=11) 
Followed up (n=102) 
Timing ol outcome measures: 
Body weight and complaints on days 0-3 
Blood samples on days 0-2 
Assessment ol well-being, tolerance and 
effectiveness on day 3 
Drop-outs (n=O) 
Completed trial: 
lntention-to-treat (n=1 02) 
Per-protocol (n=91) 
Figure 2 Patient tlow chart. 
No significant differences between the groups, how-
ever, were found in the secondary outcome measures, ie 
reduction of weight on day 1 ( difference of means 17 g, 
95% CI -75 to 109 g) and day 3 (difference of means 
18 g; 95% CI -84 to 121 g). Nor did exploratory 
analysis of the laboratory findings from days 0 to 1 and 
2 or the trend of daily complaints during the days 0-3 
reveal statistical differences regarding direction or 
quantity of the changes. The same was true for the 
assessment by physicians and patients regarding well-
Received placebo (n=106) 
Did not receive placebo, withdrawal of 
consent (n=1) 
Deviations lrom the protocol (n=3) 
Followed up (n=106) 
Timing ol outcome measures: 
Body weight and complaints on days 0-3 
Blood samples on days 0-2 
Assessment of well-being, tolerance and 
effectiveness on day 3 
Drop-outs (n=O) 
Completed trial: 
lntention-to-treat (n=1 06) 
Per-protocol (n=1 03) 
being, tolerance, and effectiveness. In both groups the 
ratings 'good' or 'very good' were given to tolerance by 
98%, to well-being by 88%, and to effectiveness by 
77% of the patients and doctors. 
The groups were comparable in some 200 baseline 
parameters (selection in Table 1 ), indicating that 
randomisation was successful. A few random differ-
ences, hovvever, had to be considered as confounding 
factors. In the run-in period ( days -3 to 0), the mean 
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Table 1 Baseline characteristics of study patients. Means (SD) or numbers (percentage) 
Thyroidinum (n=102) Placebo (n=1 06) 
Age (mean, years) 
Sex (male:female) 
Height (cm) 
51.0 (13.3) 51.8 (12.6) 
26 (25.5%):76 (74.5%) 
166.6 (6.8) 
31 (29.2%):75 (70.8%) 
167.7 (8.4) 
Body weight (on day 0, kg) 
Body mass index (on day 0, kg/m2) 
Blood pressure (mean, mmHg) 
Smoking (yes:no:no more) 
89.6 (21.1) 93.9 (19.8) 
32.2 (7.2) 33.4 (6.7) 
139/87 (28/15) 143/90 (26/15) 
15 (14.7%):71 (69.6%):16 (15.7%) 19 (17.9%):77 (72.6%):10 (9.4%) 
Fasting experience (yes:no) 
Reduction of weight (mean, g): 





576 (422) 650 (348) 
486 (337) 578 (309) 
538 (316) 616 (343) 
-125 (185) -80 (123) 
Average (day -3 to day 0) 369 (174) 443 (192) 
Table 2 Primary and secondary outcomes in weight reduction. Means (SD or 95% Cl) 









significant) as was the mean daily weight reduction 
(significant on days -2 and 0). To determine the 
impact of these baseline differences, a covariate 
adjustment was carried out using a general linear 
model (GLM, univariate and multivariate), analysing 
each confounding variable in sequence as weil as their 
joint impact on the outcome. 
After adjustment for these covariates, the signifi-
cance of the main outcome, ie the difference in weight 
reduction on day 2, became non-significant. Analysed 
individually (univariate), the single covariates wea-
kened significance as follows: difference in body weight 
on each of the days -3 through 0: to P = 0.062; weight 
reduction on day -3: to P=0.055; on day -2: to 
P = 0.083, on day -1: to P = 0.053; on day 0: to 
P 0.021. Considering ail these covariates together in 
one (multivariate) test, the P value of the main 
outcome declined to P = 0.094. After removal of two 
extremes and nine outliers, however, the difference in 
the main outcome became highly significant (P = 0.009) 
and maintained significance even after covariate 
adjustment (P = 0.043). Per-protocol analysis yielded 
similar results. 
The portion of group difference which was indepen-
dent of sex difference yielded a P value of 0.039, 
indicating that the significance of the result was not 
due to an unbalanced sex distribution between the 
treatment groups. 
Discussion 
Although initially significant, the result of this study 
was weakened by adjustment for differences at baseline 




Difference between groups 
17 (-75 to 109) 
-92 (-176 to -7)* 
18 ( -84 to 121 ) 
and thus ultimately did not refute the null hypothesis 
which denies that one dose of Thyroidinum 30cH 
affects the weight reduction of fasting patients differ-
ently than one dose of placebo. 
To meet the exacting demands of a clinical trial on a 
highly controversial subject like homeopathy19- 36 this 
study was rigorously designed, conducted, monitored, 
and audited according to the regulations for quality 
assurance of clinical trials, the EC-GCP-guidelines 
'Good Clinical Practice for Trials on Medicinal 
Products in the European Community'. The data 
quality was exceilent (virtually no missing or implau-
sible data). Comparability of both groups was assessed 
by means of some 200 parameters collected from each 
patient on 14-page case report forms: demographic 
data (marital status, occupation, education, etc), 
physical examination (10 items), diagnoses, history 
(12 disease groups), diagnostics (nine items), therapeu-
tics (injections, acupuncture, physiotherapy, hydro-
therapy, etc), medication (21 drug categories), 34 
laboratory data, 15 complaints, liquid and caloric 
intake, bowel movement, Iaxatives, etc. Apart from 
three patients who withdrew their consent before 
receiving study medication, there were no drop-outs. 
Estimation of sample size together with a stochastic 
curtailment ensured sufficient power when the trial was 
ended with 208 enrolled patients. 
Unlike most previous studies, this trial tried to 
test the efficacy of a homeopathic ultramolecular 
dilution over placebo by means of objective outcome 
measures. The clinical model was chosen according 
to observations made by doctors at the Krankenhaus 
für Naturheilweisen over several decades and based 
on pathophysiological as weil as homeopathic 
Homeopathy 
considerations. Since the (energy sparing and weight 
reduction restricting) low-T3-state of fasting patients 
can be overcome by T3 intake, administration of a 
homeopathic preparation of thyroid gland was ex-
pected to affect this system. According to homeopathic 
materia medica, Thyroidinum is reported to provoke 
many symptoms similar to 'fasting crises' eg headache, 
nausea, irritability, weakness of memory, palpitation, 
fiushes of heat, etc and thus, according to the principle 
of similars, may be homeopathically indicated in this 
' condition. To keep the number of variables to a 
minimum, treatment of patients was not completely 
individualised but on the basis of a more general 
' similarity to the main features of this clinical condition. 
According to clinical experience and homeopathic/ 
physiological considerations the increased weight 
reduction expected in the treatment group on day 1 
could possibly be followed by a secondary impairment 
of weight reduction on day 2. For lack of previous 
research and literatme on this topic, originally the 
main outcome measure was predefined as absolute 
weight reduction on day 1 after treatment. The null 
hypothesis read: there is no difference in the reduction 
of weight between the Thyroidinum and placebo group 
after administration of the study medication. Contrary 
to the original expectation, however, the semi-de-
blinded interim analysis showed less difference between 
groups on day 1 than on day 2. The time interval from 
administration of study medication (usually at 14.00) 
until measurement of body weight on the next day (at 
07.00) was 17h, to measurement on the second day 
41 h. Considering a possible delay of metabolic 
changes as well as the bipolarity of many homeopathic 
effects, it seemed moreplausible to expect the main, if 
any, effect of a remedy supposed to modulate thyroid 
metabolism and reduction of body weight at the later 
time point. These considerations prompted a revision 
of the protocol with a change of the main outcome 
measure (weight reduction on day 2 instead of day 1). 
However, since this modification was not communi-
cated to study physicians and hospital staff or patients, 
the trial was continued under the same conditions, 
' without any reason for bias or confusion. 
Ultimately, the difference between the groups in 
weight reduction 2 days after medication was signifi-
cant (P = 0.034), 37 but covariate adjustment for base-
line imbalances weakened the P value to levels of 0.083 
and 0.094. No significance would have been achieved 
had the original main outcome measure (weight 
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reduction on day 1) not been changed (P 0.71), or 
had the analysis of the amended outcome parameter 
(weight reduction on day 2) been confined only to 
those patients recruited after the interim analysis was 
performed (P 0.33). In view of these facts, the null 
hypothesis can hardly be rejected. 
Post-hoc inspection of the chart of the daily weight 
reduction in each group, however, suggests an alter-
native interpretation of the data. In the Thyroidinum 
group (which had lower average body weight at 
baseline) the weight reduction on five of the 7 days 
was less than in the placebo group, so the really odd 
results seem to appear on days 1 and 3 when this 
difference is inverted (see Figure 3). Had the main 
outcome measure-instead of emphasizing the absolute 
amount of weight reduction-been predefined as 
change on day 1 from the mean baseline difference 
between the groups in weight reduction on day -3 to 
day 0 (-74 g [ = 369 g-443 g, see Tables 1 and 3]), the 
result would have shown greater reduction of weight in 
the Thyroidinum group on day 1 (change from baseline 
average difference: 91 g [ = 7 4 g baseline difference + 17 g 
difference on day 1, see Tables 1-3], 95% CI -7 to 
190 g, P=0.070). Using body mass index instead of 
body weight and percentage of reduction instead of 
absolute reduction this finding would have been 
significant (change from baseline difference 0.12% of 
BMI, 95% CI 0.01-0.23%, P 0.034). It would be 
robust to covariate adjustment. This result would be 
consistent with the initial expectation of an increase of 
weight loss, ie hyperthyroid effect, on day 1 after 
treatment. Although da ta-driven post-hoc testing of this 
kind has no confirmative value,38-49 these speculations 
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Figure 3 Daily reduction of body weight 3 days before and 3 
days after stagnation/increase of weight (11=208, intention-to-
treat). 
Table 3 Post-hoc findings in weight reduction. Means (SO or 95% Cl) 
Baseline average weight reduction (days -3 to 0) (g) 














Difference between groups 
-74 (-121 to -23) 
91 (-7 to 190)* 
-17 (-106 to 72) 
93 (-24 to 210) 
*Using BMI instead of body weight and change from percentual instead of absolute reduction, this difference between groups would be 
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W ould these results be compatible with homeopathic 
doctrine, anyway? According to Hahnemann, primary 
effects of a remedy are often followed by opposite 
secondary aftereffects, eg initial alertness and subse-
quent drowsiness after coffee. Horneapathie materia 
medica demonstrates that Thyroidinum in both low and 
high potencies has shown symptoms of hyperthroidism 
as weil as hypothyroidism suggesting the possibility of 
catabolic and anabolic effects, respectively. The phe-
nomenon of bipolarity is widely acknowledged in the 
homeopathic literature. Based on refiections of this 
kind as weil as on previous clinical observations, the 
expectation was a Stimulation of weight reduction on 
the day after treatment, possibly followed by a reverse 
effect on the subsequent day. Endler et al found a 
decrease of climbing activity of tadpoles after admin-
istration of thyroxine 30x16- 18 suggesting a hypothyr-
oid effect of this potency, consistent with the findings 
presented here of impaired weight reduction on the 
second day after treatment. Both results suggest a 
hypothyroid effect of the 30th potency. Nevertheless 
the apparent increase of weight reduction on the first 
day after treatment is likely to be the primary effect. 
Neither the claim of an increase on day 1 nor of a 
decrease on day 2 of the daily weight reduction, 
however, is corroborated by the objective and sub-
jective secondary outcomes which failed to show 
corresponding differences between the groups, in terms 
of Iabaratory findings and daily complaints. This 
discrepancy casts additional doubt on the validity of 
the isolated result. Certainly, a difference of 92 g in 
weight reduction 2 days after medication is not 
clinically relevant particularly when its direction is 
the opposite of what fasting patients desire. However, 
a positive change of 0.12% in daily BMI reduction 1 
day after medication (increased weight reduction) is 
not completely irrelevant because it helps patients to 
overcome their 'fasting crisis' more quickly and 
supports the remedy's efficacy in this indication. 
In spite of the puzzling results of this study, in an 
under-researched field like homeopathy it may still be a 
valid contribution to finding a clinical model for 
proving its intriguing claim of efficacy of the ultra-
molecular dilutions. The outcome measures of this 
study were certainly neither appropriate nor sophisti-
cated enough, but replication, eg on the basis of 
changes in daily percental reduction of body mass 
index, may be of interest. 
Conclusion 
Despite meeting high-quality standards and assunng 
randomisation and blind assignment, a random 
imbalance of a few prognostically important baseline 
parameters lessened the otherwise significant result of 
the study. Due to the Iack of previous research and 
literature, the main outcome measure was predefined in 
such a way that no convincing evidence \vas detected 
Homeopathy 
for an alleged effect of an ultramolecular dilution of 
Thyroidinum on the weight reduction offasting patients 
after a stagnation/increase of weight. Posthoc analysis, 
however, suggests that by using the same clinical model 
with more appropriate and sophisticated outcome 
measures, efficacy may be dernonstrahle in replication 
studies. In conclusion, this study failed to disprove the 
null hypothesis related to this outcome measure and 
the preparation of this homeopathic remedy for 
this clinical indication, but should not be misunder-
stood as a refutation of the principles of homeopathy 
at !arge. 
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